HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines

HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: بهزاد برادران , نویده حق نواز , داریوش شانه بندی , توحید کاظمی

کلمات کلیدی: Breast cancer; HER2; miR- 21; miR-203; oncomiR; paclitaxe

نشریه: 0 , 0 , 0 , 2017

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله بهزاد برادران
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه مرکز تحقیقات ایمونولوژی
کد مقاله 62343
عنوان فارسی مقاله HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines
عنوان لاتین مقاله HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines
ناشر 6
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق) ARTIFICIAL CELLS, NANOMEDICINE, AND BIOTECHNOLOGY
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت http://dx.doi.org/10.1080/21691401.2017.1326927

خلاصه مقاله
hide/show

Introduction: MicroRNAs (miRNAs) are short non-coding single-stranded RNAs. Involving in post-transcriptional gene silencing, miRNAs are thought to play important roles in many cancers such as breast cancer. Paclitaxel is used widely in the treatment of breast cancer. In this study, we investigated the effect of paclitaxel treatment on the expression levels of two oncomirs (oncomiRs), miR-21 and miR- 203, in breast cancer cell lines. Materials and methods: MTT assay was performed to determine IC50 of paclitaxel for human breast cancer cell lines including MCF-7, MDA-MB-231, SKBR3 and BT-474. After RNA extraction and cDNA synthesis, the expression levels of miRNAs were then quantitatively evaluated using real-time PCR. Results: Our results showed that after treatment, the expression levels of both miR-21 and miR-203 were significantly increased in HER2-positive cell lines, BT-474 and SKBR3. HER2-negative cell lines, MCF- 7 and MDA-MB-231, in contrast had significantly decreased expression of both assessed oncomiRs. Conclusion: Our results showed that the expression levels of oncomiRs were increased in HER-2 positive breast cancer cells and this finding is in line with previous studies. Our findings present a probable mechanism of resistance against paclitaxel chemotherapy in HER2-positive breast cancers.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
بهزاد برادرانپنجم
نویده حق نوازاول
داریوش شانه بندیچهارم
توحید کاظمیششم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
186-HER2 positivity may confer resistance to therapy.pdf1396/11/25947815دانلود